

**S1 Table.** Characteristics of patients who can received conversion surgery versus no conversion surgery group

Characteristic	Conversion surgery group	No conversion surgery group	p-value
Age (yr)			
< 65	28 (84.8)	61 (83.6)	> 0.99
≥ 65	5 (15.2)	12 (16.4)	
ECOG PS score			
0	26 (78.8)	48 (65.8)	0.253
1	7 (21.2)	25 (34.2)	
Sex			
Female	4 (12.1)	9 (12.3)	> 0.99
Male	29 (87.9)	64 (87.7)	
Platelet ( $\times 10^9/L$ )			
< 100	5 (15.1)	7 (9.6)	0.509
≥ 100	28 (84.8)	66 (90.4)	
ALT (IU/L)			
< 40	15 (45.5)	33 (45.2)	> 0.99
≥ 40	18 (54.5)	40 (54.8)	
AST (IU/L)			
< 40	11 (33.3)	11 (15.1)	0.040
≥ 40	22 (66.7)	62 (84.9)	
Total bilirubin ( $\mu\text{mol/L}$ )			
< 34	31 (93.9)	70 (95.9)	> 0.99
≥ 34	2 (6.1)	3 (4.1)	
Albumin (g/L)			
< 35	5 (15.2)	19 (26.0)	0.316
≥ 35	28 (84.8)	54 (74.0)	
ALBI grade			
1	14 (42.4)	32 (43.8)	> 0.99
2	19 (57.6)	41 (56.2)	
AFP (ng/mL)			
< 400	13 (39.4)	23 (31.5)	0.508
≥ 400	20 (60.6)	50 (68.5)	
HBsAg			
Negative	2 (6.1)	7 (9.6)	0.717
Positive	31 (93.9)	66 (90.4)	
Child-Pugh			
A	3 (9.1)	7 (9.6)	> 0.99
B	30 (90.9)	66 (90.4)	
Maximum tumor size (cm)			
< 5	1 (3.0)	12 (16.4)	0.060
≥ 5	32 (97.0)	61 (83.6)	
Tumor number			
Solitary	13 (39.4)	17 (23.3)	0.106
Multiple	20 (60.6)	56 (76.7)	
Extent of PVTT			
Non-VP4	19 (57.6)	46 (63.0)	0.668
VP4	14 (42.4)	27 (37.0)	
Extrahepatic metastases			
Yes	0	15 (20.5)	0.005
No	33 (100)	58 (79.5)	
mRECIST			

CR or PR	32 (97.0)	42 (57.5)	< 0.001
SD or PD	1 (3.0)	31 (42.5)	

---

Values are presented as number (%). AFP, alpha-fetoprotein; ALBI, albumin-bilirubin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CR, complete response; ECOG PS, Eastern Cooperative Oncology Group performance status; HBsAg, hepatitis B surface antigen; mRECIST, modified Response Evaluation Criteria in Solid Tumors; PD, progressive disease; PR, partial response; PVTT, portal vein tumor thrombus; SD, stable disease.